Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248287 · ClinicalTrials.gov registry record · Phase 2
PhII ICb With/Without Erbitux in MBC Pts
A Phase 2 study of Metastatic Breast Cancer, sponsored by US Oncology Research.
- Active
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT00248287 is a Phase 2 study of Metastatic Breast Cancer that is active but no longer recruiting, run by US Oncology Research. The registered enrollment target is 154 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00248287, a Phase 2 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by US Oncology Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
Conditions Studied
Interventions
- DRUG Irinotecan + Carboplatin
- DRUG irinotecan + Carboplatin + erbitux
Study Locations (20)
Florida
- Melbourne Internal Medicine Associates - Melbourne
- Florida Cancer Institute - New Port Richey
- Ocala Oncology Center - Ocala
- Cancer Centers of Florida, P.A. - Ocoee
Arizona
- Hematology Oncology Asscociates - Phoenix
- Northern AZ Hematology & Oncology Assoc - Sedona
Missouri
- Missouri Cancer Associates - Columbia
- Arch Medical Services, Inc - St Louis
New Jersey
- Hematology-Oncology Associates of NNJ, P.A. - Morristown
- Summit Medical Group - Summit
Alabama
- Birmingham Hematology and Oncology - Birmingham
Colorado
- Rocky Mountain Cancer Center-Rose - Denver
Connecticut
- Northwestern Connecticut Oncology Hematology Associates - Torrington
Illinois
- Hematology Oncology Associates of IL - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2005-07-28 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248287
The ClinicalTrials.gov registry entry for NCT00248287 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (25% lower). The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Irinotecan + Carboplatin is the first listed.
NCT00248287 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Arizona, Missouri.
Frequently Asked Questions
What is clinical trial NCT00248287 about?
NCT00248287 is a clinical study titled "PhII ICb With/Without Erbitux in MBC Pts". The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
What is the current status of trial NCT00248287?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2005-07-28. Estimated completion is 2026-12.
What conditions does trial NCT00248287 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT00248287?
The interventions under investigation include: Irinotecan + Carboplatin (DRUG), irinotecan + Carboplatin + erbitux (DRUG).
Who is sponsoring clinical trial NCT00248287?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00248287 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.